Cara Therapeutics Inc. (NASDAQ:CARA) went down by -7.96% from its latest closing price compared to the recent 1-year high of $29.65. The company’s stock price has collected -50.84% of loss in the last five trading sessions. Press Release reported on 04/29/21 that Cara Therapeutics Announces Topline Results From KARE Phase 2 Dose-Ranging Trial of Oral KORSUVA(TM) in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus
Is It Worth Investing in Cara Therapeutics Inc. (NASDAQ :CARA) Right Now?
Cara Therapeutics Inc. (NASDAQ:CARA) scored a price-to-earnings ratio above its average ratio, recording 392.42 x from its present earnings ratio. Plus, the 36-month beta value for CARA is at 1.12. Opinions of the stock are interesting as 7 analysts out of 8 who provided ratings for Cara Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $29.13. CARA currently public float of 41.83M and currently shorts hold a 8.56% ratio of that float. Today, the average trading volume of CARA was 1.19M shares.
CARA’s Market Performance
CARA stocks went down by -50.84% for the week, with a monthly drop of -40.35% and a quarterly performance of -30.75%, while its annual performance rate touched -12.62%. The volatility ratio for the week stands at 7.57% while the volatility levels for the past 30 days are set at 6.00% for Cara Therapeutics Inc.. The simple moving average for the period of the last 20 days is -50.75% for CARA stocks with a simple moving average of -25.83% for the last 200 days.
Analysts’ Opinion of CARA
Many brokerage firms have already submitted their reports for CARA stocks, with H.C. Wainwright repeating the rating for CARA by listing it as a “Buy.” The predicted price for CARA in the upcoming period, according to H.C. Wainwright is $33 based on the research report published on April 21st of the previous year 2020.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see CARA reach a price target of $30, previously predicting the price at $31. The rating they have provided for CARA stocks is “Buy” according to the report published on August 12th, 2019.
Laidlaw gave a rating of “Buy” to CARA, setting the target price at $32 in the report published on May 29th of the previous year.
CARA Trading at -41.58% from the 50-Day Moving Average
After a stumble in the market that brought CARA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.32% of loss for the given period.
Volatility was left at 6.00%, however, over the last 30 days, the volatility rate increased by 7.57%, as shares sank -40.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -34.96% lower at present.
During the last 5 trading sessions, CARA fell by -50.84%, which changed the moving average for the period of 200-days by -27.73% in comparison to the 20-day moving average, which settled at $25.85. In addition, Cara Therapeutics Inc. saw -14.41% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at CARA starting from Goncalves Joana, who sale 3,000 shares at the price of $27.63 back on Apr 21. After this action, Goncalves Joana now owns 43,610 shares of Cara Therapeutics Inc., valued at $82,890 using the latest closing price.
Goncalves Joana, the Chief Medical Officer of Cara Therapeutics Inc., sale 3,000 shares at $19.65 during a trade that took place back on Mar 22, which means that Goncalves Joana is holding 30,610 shares at $58,950 based on the most recent closing price.
Stock Fundamentals for CARA
Current profitability levels for the company are sitting at:
- +3.99 for the present operating margin
The net margin for Cara Therapeutics Inc. stands at +6.23. The total capital return value is set at 2.42, while invested capital returns managed to touch 3.80. Equity return is now at value 5.00, with 4.30 for asset returns.
Based on Cara Therapeutics Inc. (CARA), the company’s capital structure generated 2.12 points at debt to equity in total, while total debt to capital is 2.07. Total debt to assets is 1.95, with long-term debt to equity ratio resting at 1.48. Finally, the long-term debt to capital ratio is 1.44.
When we switch over and look at the enterprise to sales, we see a ratio of 4.07, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 70.15 and the total asset turnover is 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.55.